Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 6Completed 5Withdrawn 3Terminated 3Recruiting 3Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 11Carcinoma, Ovarian Epithelial 4Small Cell Lung Carcinoma 2Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrent/ Advanced Stage Endometrial Cancer Patients 1Platinum-resistant Ovarian Cancer 1Pancreatic Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Nausea 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Kenny-Caffey syndrome, Type 1 1Gonadal Disorders 1Glioblastoma 1Genital Neoplasms, Female 1Genital Diseases, Female 1Endometrial Neoplasms 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1

Interventions

Cyclophosphamide 77Docetaxel 69Capecitabine 64Trastuzumab 61Paclitaxel 50Tamoxifen 47Epirubicin 47Letrozole 44pyrotinib 40Fulvestrant 37Doxorubicin 35Vinorelbine 33Radiotherapy 32Carboplatin 32Anastrozole 28exemestane 27Neoadjuvant Therapy 24Drug Therapy 22Fluorouracil 21palbociclib 20Exercise 20Chemotherapy, Adjuvant 19Bevacizumab 18pertuzumab 16Goserelin 16Cisplatin 16liposomal doxorubicin 15Mammography 14Gemcitabine 14Blood Specimen Collection 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Neoplasms × niraparib × Clear all
NCT04764084 2021-02-21

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Peking University Cancer Hospital & Institute

Phase 1 Unknown
52 enrolled
BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡